Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance

A case-control study

Michael A. Thompson, Robert A. Kyle, L. Joseph Melton, Matthew F. Plevak, S Vincent Rajkumar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) and C-reactive protein (CRP, a surrogate marker for IL-6) are important in monoclonal gammopathy of undetermined significance (MGUS) and myeloma. Smoking and obesity may elevate CRP levels, while statins decrease CRP levels. A case-control study in 200 MGUS patients found that statin use, smoking history and obesity do not affect MGUS progression.

Original languageEnglish (US)
Pages (from-to)626-628
Number of pages3
JournalHaematologica
Volume89
Issue number5
StatePublished - May 2004

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Case-Control Studies
Obesity
Smoking
Interleukin-6
C-Reactive Protein
Biomarkers
History

Keywords

  • Hydroxymethylglutaryl-CoA reductose inhibitors
  • MGUS
  • Myeloma
  • Statin

ASJC Scopus subject areas

  • Hematology

Cite this

Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance : A case-control study. / Thompson, Michael A.; Kyle, Robert A.; Melton, L. Joseph; Plevak, Matthew F.; Rajkumar, S Vincent.

In: Haematologica, Vol. 89, No. 5, 05.2004, p. 626-628.

Research output: Contribution to journalArticle

Thompson, Michael A. ; Kyle, Robert A. ; Melton, L. Joseph ; Plevak, Matthew F. ; Rajkumar, S Vincent. / Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance : A case-control study. In: Haematologica. 2004 ; Vol. 89, No. 5. pp. 626-628.
@article{dbfc1301ac3a49cc819c2be80fbf15b7,
title = "Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: A case-control study",
abstract = "Interleukin-6 (IL-6) and C-reactive protein (CRP, a surrogate marker for IL-6) are important in monoclonal gammopathy of undetermined significance (MGUS) and myeloma. Smoking and obesity may elevate CRP levels, while statins decrease CRP levels. A case-control study in 200 MGUS patients found that statin use, smoking history and obesity do not affect MGUS progression.",
keywords = "Hydroxymethylglutaryl-CoA reductose inhibitors, MGUS, Myeloma, Statin",
author = "Thompson, {Michael A.} and Kyle, {Robert A.} and Melton, {L. Joseph} and Plevak, {Matthew F.} and Rajkumar, {S Vincent}",
year = "2004",
month = "5",
language = "English (US)",
volume = "89",
pages = "626--628",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "5",

}

TY - JOUR

T1 - Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance

T2 - A case-control study

AU - Thompson, Michael A.

AU - Kyle, Robert A.

AU - Melton, L. Joseph

AU - Plevak, Matthew F.

AU - Rajkumar, S Vincent

PY - 2004/5

Y1 - 2004/5

N2 - Interleukin-6 (IL-6) and C-reactive protein (CRP, a surrogate marker for IL-6) are important in monoclonal gammopathy of undetermined significance (MGUS) and myeloma. Smoking and obesity may elevate CRP levels, while statins decrease CRP levels. A case-control study in 200 MGUS patients found that statin use, smoking history and obesity do not affect MGUS progression.

AB - Interleukin-6 (IL-6) and C-reactive protein (CRP, a surrogate marker for IL-6) are important in monoclonal gammopathy of undetermined significance (MGUS) and myeloma. Smoking and obesity may elevate CRP levels, while statins decrease CRP levels. A case-control study in 200 MGUS patients found that statin use, smoking history and obesity do not affect MGUS progression.

KW - Hydroxymethylglutaryl-CoA reductose inhibitors

KW - MGUS

KW - Myeloma

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=2542418095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542418095&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 626

EP - 628

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -